1 week 15
Extreme 15
25.49
1 month 15
Extreme 15
25.49
Current year 15
Extreme 15
25.49
1 year 15
Extreme 15
25.49
3 years 15
Extreme 15
25.49
5 years 15
Extreme 15
25.49
10 years 15
Extreme 15
25.49
Manager TitleAgeSince
Corporate Officer/Principal - -
Chief Executive Officer 37 01/06/2017
Director of Finance/CFO 57 01/12/2021
Director TitleAgeSince
Director/Board Member 37 01/06/2017
Director/Board Member 54 01/03/2021
Director/Board Member 60 01/07/2025
Date Insider Type Main position Quantity % Market Cap.
7/23/26 A Other

Founder

681,683 8.0236%
7/23/26 A OtherCompany 1,054,828 12.4156%
7/23/26 A Other

Executive/Senior Manager

122,027 1.4363%
Change 5-day change 1-year change 3-year change Capi.($)
+44.33%0.00% - - 381M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average +4.63%+0.75%+54.56%+106.44% 24.57B
Weighted average by Cap. +0.55%+0.91%+74.42%+136.27%

Financials

2024 2025
Net sales 27.41M 24.08M 22.39M 20.55M 38.61M 2.64B 39.2M 266M 104M 1.3B 103M 101M 4.49B 51.17M 44.95M 41.8M 38.36M 72.07M 4.93B 73.18M 496M 194M 2.42B 192M 188M 8.38B
Net income -47.79M -41.97M -39.03M -35.82M -67.3M -4.6B -68.33M -463M -181M -2.26B -179M -176M -7.82B -21.81M -19.15M -17.81M -16.35M -30.71M -2.1B -31.19M -212M -82.64M -1.03B -81.87M -80.1M -3.57B
Net Debt - -
Logo Scribe Therapeutics Inc.
Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. It focuses on cardiovascular and metabolic (CVM) diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease (ASCVD). The Company's lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on its ELXR technology and is designed to durably lower LDL-C for years to decades by repressing the expression of PCSK9, a genetically and clinically validated target. STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering the underlying DNA sequence. Its pipeline also includes STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively.
Employees
89
Date Price Change Volume
24/07/26 $21.65 +44.33% 990,795
23/07/26 $15.00 0.00% 0
  1. Stock Market
  2. Stocks
  3. SCTX Stock